The Effects of Repeated Bouts of Downhill Running and Curcumin Supplementation on Arterial Stiffness During Recovery (Cur)
|ClinicalTrials.gov Identifier: NCT02281981|
Recruitment Status : Unknown
Verified September 2015 by Dr. Jamie Burr, University of Prince Edward Island.
Recruitment status was: Active, not recruiting
First Posted : November 4, 2014
Last Update Posted : September 17, 2015
|Condition or disease||Intervention/treatment||Phase|
|Vascular Stiffness||Dietary Supplement: Curcumin Dietary Supplement: Placebo||Phase 1|
Baseline Participants will report to the lab on day one to have basic anthropometry and clinical measures performed. Following measures of height, weight, blood pressure, blood lipids (fasting glucose), creatine kinase, high sensitivity C-reactive protein (HS-CRP) and interleukin-6 (IL-6) participants will be allowed to eat a small standardized snack. Participants will then have measures of baseline muscle soreness and leg strength measured prior to a VO2max test on a cycle ergometer.
Muscle Soreness will be measured using a standard 10cm analogue scale and girth of the thigh will be recorded to account for possible alterations owing to local inflammation/oedema./ Creatine Kinase (CK) will be tracked as a measure of damage.
The test termination criteria for the VO2max will include: volitional fatigue, a participant rating of perceived exertion of 19-20 (on a scale from 0-20), a plateau in O2 uptake with increasing workload, or and RER of >1.15. The VT of each participant will be noted to compare with values post- training.
Testing Day 2 - This day will occur at least 1 full day (48h) following VO2max testing.
Participants will arrive at the lab having consumed a standardized breakfast. Prior to the downhill run, measures of pulse wave velocity (PWV), heart rate variability (HRV), flow mediated dilatation (FMD) will be collected according to the protocols to follow. Participants will then perform a 40 minute downhill run at a grade of -12 percent using a speed that elicits a VO2 of approximately 60% of the maximum value achieved during the max test.
Arterial stiffness will be determined using a Sphygmocor CPVH pulse wave applanation tonomoter (Atcor Medical). This device measures arterial pulse waves non-invasively through the skin. By matching pulse wave arrival with heart beats (through a standard ECG tracing) and measuring the distance between points we can calculate travel time (or velocity). We will also use this same device to analyze the shape of the pulse wave, which will give us information about reflected pulse waves (and thus the stiffness of the arterial tree).
Follow-up: At 24h, 48h, and 72h post exercise, participants will return to the lab to have all of the non-exercise measures repeated (see figure 1). This will allow temporal tracking over time.
1) The anti-inflammatory potential of Curcumin supplementation should improve post-exercise recovery. 2) Repeated bouts of eccentrically biased downhill running should produce a prophylactic effect and reduce arterial stiffness and recovery time
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||The Effects of Repeated Bouts of Downhill Running and Curcumin Supplementation on Arterial Stiffness During Recovery|
|Study Start Date :||November 2014|
|Estimated Primary Completion Date :||March 2016|
|Estimated Study Completion Date :||May 2016|
Experimental: Curcumin supplement
200 mg, curcuminoids, 7d of supplementation in capsular form
Dietary Supplement: Curcumin
333mg CurcuWin OAHTCUR002-2014
Other Name: Tumeric extract
Placebo Comparator: Placebo
Dietary Supplement: Placebo
- Arterial Stiffness [ Time Frame: Every 24 hr up to 72hr post baseline ]This will be measured using arterial tonometry
- Blood measures of inflammation and muscle damage [ Time Frame: Every 24 hr up to 72hr post baseline ]Interleukin-6, highsensitivity C-reactive protein, Creatine Kinase
- Delayed onset muscle soreness [ Time Frame: Every 24 hr up to 72hr post baseline ]Subjective analogue scale
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02281981
|Principal Investigator:||Jamie F Burr, PhD||UPEI|